Indivior emergency opioid overdose treatment gains US FDA approval

London-listed Indivior (LSE: INDV) saw its shares edge up a modest 1.4% to 1,522 pence this morning after it revealed that the US Food and Drug Administration (FDA) has approved Opvee (nalmefene) nasal spray.

Opvee is indication for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.

Nalmefene is an opioid receptor antagonist that provides fast onset and long duration reversal of opioid-induced respiratory depression, which is the primary cause of opioid overdose injury and death.